Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) Return on Invested Capital (2018 - 2025)

Protagonist Therapeutics' Return on Invested Capital history spans 6 years, with the latest figure at 0.25% for Q4 2025.

  • For Q4 2025, Return on Invested Capital fell 67.0% year-over-year to 0.25%; the TTM value through Dec 2025 reached 0.25%, down 67.0%, while the annual FY2025 figure was 0.25%, 74.0% down from the prior year.
  • Return on Invested Capital for Q4 2025 was 0.25% at Protagonist Therapeutics, down from 0.03% in the prior quarter.
  • Across five years, Return on Invested Capital topped out at 0.49% in Q1 2024 and bottomed at 0.26% in Q2 2021.
  • The 3-year median for Return on Invested Capital is 0.04% (2025), against an average of 0.12%.
  • The largest annual shift saw Return on Invested Capital skyrocketed 94bps in 2021 before it tumbled -67bps in 2025.
  • A 3-year view of Return on Invested Capital shows it stood at 0.26% in 2021, then skyrocketed by 256bps to 0.41% in 2024, then crashed by -161bps to 0.25% in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Return on Invested Capital are 0.25% (Q4 2025), 0.03% (Q3 2025), and 0.03% (Q2 2025).